The International Contrast Ultrasound Society (ICUS)

CHICAGO--(BUSINESS WIRE) dated 10/4/13 -- Physicians announced today the results of a study showing that a safe, radiation-free diagnostic scan can be used in children with cancer to assess tumor response to therapy.

Contrast-enhanced ultrasound (CEUS) imaging "is emerging as a very good and safe mechanism for evaluating the effectiveness of cancer therapy in children without having to use CT, which exposes the child to ionizing radiation," Dr. Jamie Coleman told the International Contrast Ultrasound Society (ICUS) at their annual conference in Chicago.      

Click here to see full media release

Study finds non-invasive ultrasound scan more accurate than MRI and PSA
CHICAGO--(BUSINESS WIRE) dated 10/3/13 - Prostate cancer can be detected simply and more accurately with a radiation-free, non-invasive screening test, according to findings announced today at an international physician conference.

The findings, reported at the International Contrast Ultrasound Society (ICUS) annual conference, found contrast-enhanced ultrasound imaging (CEUS) exams can provide more accurate results than either MRI, PSA or conventional ultrasound imaging.

Click here to see full media release

The Medicare Payment Advisory Commission (MedPAC) June 2013 Report to Congress portends some seismic changes in echocardiogram reimbursement. MedPAC, an independent Congressional agency established to advise the U.S. Congress on issues affecting the Medicare program, recommended in 2012 that payment rates for office visits should be the same whether care is provided in a hospital outpatient department or freestanding physician office. The June 2013 Report goes further, recommending 66 groups of services where outpatient department (OPD) payment could be aligned with the physician office rate.
Of particular concern to ICUS physicians, the impact on cardiology could be significant if Congress or CMS adopts the MedPAC recommendations. The net effect is to regress hospital outpatient rates to physician fee for service rates. Why is this a concern? Cardiology practices have trended toward hospital integration over the past few years, based largely on much higher imaging reimbursement in the hospital outpatient environment (and declining reimbursements and rising operational costs for private practice office based imaging, with total cuts of about 70% over a recent two year period).
MedPAC notes that when a level II echocardiogram without contrast is provided in a freestanding office, the payment to the physician is $188.31 (physician work, plus PLI, plus nonfacility PE) (Table 2-3 of the 2013 Report). If the service is provided in a hospital OPD, the total payment equals $452.89 (physician work, plus PLI, plus facility PE, plus OPPS payment). However, a policy that aligns rates across settings would see the OPPS rate drop to $125.91 and the total payment fall to $188.31, which is the same rate that is paid in a freestanding office.
The MedPAC release can be found at the link below, see "Reducing Medicare Payment Differences Across Sites of Care":
Full 300 page report is at the link below, see "Medicare Payment Differences Across Ambulatory Settings," pages xii and Chapter 2:

Upon Approval, GE Healthcare's Oslo Facility Will Provide Stock to the US Becoming Only Contrast Media Manufacturer to Supply Its Own Stock to the US Market

PRINCETON, NJ, January 15, 2013 – GE Healthcare today announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture OptisonTM (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility. Optison is a contrast agent that may improve the visualization of the left ventricular border – an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. Upon approval, GE Healthcare will provide supply of Optison to the US market from its manufacturing facility in Oslo, becoming the only contrast media manufacturer to supply its own stock for the US.

For the full article, please click on the attached document.

CHICAGO  -- Breast cancer can be detected more accurately with a radiation-free, non-invasive screening test according to a study described today. The findings, released at the International Contrast Ultrasound Society (ICUS) 27th Annual Conference, found contrast-enhanced ultrasound imaging (CEUS) exams provide more accurate results than either MRI or conventional ultrasound imaging.

In a multi-center study of 351 women in Japan,  CEUS identified focal breast lesions with more accuracy, having fewer false positives and fewer false negatives when compared to MRI and unenhanced ultrasound imaging, according to Dr. Fuminori Moriyasu, medical advisor for the study at Tokyo Medical University.

"CEUS is an excellent diagnostic imaging tool that helps differentiate benign from malignant tumors without exposing patients to ionizing radiation," Dr. Moriyasu said. His study led to the recent approval in Japan of Sonozoid, an ultrasound contrast agent marketed by GE Healthcare.
Sonozoid is a liquid suspension of tiny gas microbubbles that can be injected into a patient's arm vein during an ultrasound exam to enhance the ultrasound signals, improving the clarity and accuracy of the ultrasound image.  Sonozoid is expelled from the body within minutes.

"These findings provide an exciting new radiation-free option for detecting breast cancer and assessing treatment," according to Dr. Sharon Mulvagh, a cardiologist at Mayo Clinic and women's health researcher.  The Japanese study is especially noteworthy because other studies show that CEUS can lower the overall cost of diagnostic imaging by improving the usefulness of frontline ultrasound scans, thereby reducing the need for redundant downstream testing.

"The potential impact of this is huge for women," Dr. Mulvagh added. She said that CEUS is readily accessible, safe and avoids exposing women to radiation.

The Phase 3 study showed that Sonozoid was accurate in 87% of patients, compared to 69.5% accuracy of MRI and 65.5% accuracy of conventional ultrasound without a contrast agent, according to Dr. Moriyasu.

“A new approval for characterization of breast masses holds great promise for women’s health”, added Stephanie Wilson, a radiologist at the University of Calgary and a Vice president of ICUS.
Sonozoid is not approved for use in the United States.  However, two other ultrasound contrast agents -- Optison (GE Healthcare) and Definity (Lantheus Medical Imaging) -- are FDA-approved for cardiac imaging in the United States.  In addition, Sonovue (Bracco) is used in Europe and elsewhere for imaging tumors and organ systems throughout the body. Additional applications of these ultrasound contrast agents are under review worldwide.

ABOUT ICUS: ICUS is an international, multi-disciplinary, not-for-profit medical society that is exclusively dedicated to advancing the use of contrast enhanced ultrasound diagnostic imaging to improve patient care worldwide. Founded in September 2008, ICUS brings together physicians, scientists, and other ultrasound imaging professionals from over 55 countries. ICUS members represent diverse specialties such as cardiology, radiology, vascular imaging, gastro-intestinal imaging, oncology, OB-GYN, and hepatology. For more information about ICUS, please visit


Mark Weller, 202.408.3933
This email address is being protected from spambots. You need JavaScript enabled to view it.

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:






ICUS Tweets

Detect liver cancer effectively and more cheaply, without harmful radiation imaging or costly MRI eqpt. Read more:
Lose weight while you sleep? Maybe soon! Read more at:
Follow Bubble Conference 2016 comment at #bubble2016

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS News